Abstract:BACKGROUND AND AIMS:Fatty acid translocase CD36 (CD36) is a membrane protein with multiple immuno-metabolic functions. Palmitoylation has been suggested to regulate the distribution and functions of CD36, but little is known about its significance in non-alcoholic steatohepatitis (NASH). METHODS:Human liver tissue samples were obtained from patients undergoing liver biopsy for diagnostic purposes. CD36 knockout mice were injected with lentiviral vectors expressing wild-type CD36 or CD36 with mutated palmitoylation sites. Liver histology, immunofluorescence, mRNA expression profile, subcellular distributions and functions of CD36 protein were assessed. RESULTS:The localization of CD36 on the plasma membrane of hepatocytes was markedly increased in patients with NASH compared to patients with normal liver and those with simple steatosis. Increased CD36 palmitoylation and increased localization of CD36 on the plasma membrane of hepatocytes were also observed in livers of mice with NASH. Furthermore, inhibition of CD36 palmitoylation protected mice from developing NASH. The absence of palmitoylation decreased CD36 protein hydrophobicity reducing its localization on the plasma membrane as well as in lipid raft of hepatocytes. Consequently, a lack of palmitoylation decreased fatty acid uptake and CD36/Fyn/Lyn complex in HepG2 cells. Inhibition of CD36 palmitoylation not only ameliorated intracellular lipid accumulation via activation of the AMPK pathway, but also inhibited the inflammatory response through the inhibition of the JNK signaling pathway. CONCLUSIONS:Our findings demonstrate the key role of palmitoylation in regulating CD36 distributions and its functions in NASH. Inhibition of CD36 palmitoylation may represent an effective therapeutic strategy in patients with NASH. LAY SUMMARY:Fatty acid translocase CD36 (CD36) is a multifunctional membrane protein which contributes to the development of liver steatosis. In the present study, we demonstrated that the localization of CD36 on the plasma membrane of hepatocytes is increased in patients with non-alcoholic steatohepatitis. Blocking the palmitoylation of CD36 reduces CD36 distribution in hepatocyte plasma membranes and protects mice from non-alcoholic steatohepatitis. The inhibition of CD36 palmitoylation not only improved fatty acid metabolic disorders but also reduced the inflammatory response in vitro and in vivo. The present study suggests that CD36 palmitoylation is important for non-alcoholic steatohepatitis development and inhibition of CD36 palmitoylation could be used to cure non-alcoholic steatohepatitis.

CD36 Promotes De Novo Lipogenesis in Hepatocytes Through INSIG2-dependent SREBP1 Processing

CD36 Plays a Negative Role in the Regulation of Lipophagy in Hepatocytes Through an AMPK-dependent Pathway

Systemic loss of CD36 aggravates NAFLD-related HCC through MEK1/2-ERK1/2 signaling pathway

CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.

O-GlcNAcylation Promotes the Progression of Nonalcoholic Fatty Liver Disease by Upregulating the Expression and Function of CD36

Cd36 Level And Trafficking Are Determinants Of Lipolysis In Adipocytes

Hepatic CREBZF Couples Insulin to Lipogenesis by Inhibiting Insig activity and Contributes to Hepatic Steatosis in Diet-Induced Insulin-Resistant Mice.

Hepatocyte CD36 protects mice from NASH diet-induced liver injury and fibrosis via blocking N1ICD production

Hepatic Fatty Acid Transporter Cd36 is a Common Target of LXR, PXR, and PPARgamma in Promoting Steatosis.

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Cluster of Differentiation 36 Deficiency Aggravates Macrophage Infiltration and Hepatic Inflammation by Upregulating Monocyte Chemotactic Protein-1 Expression of Hepatocytes Through Histone Deacetylase 2-Dependent Pathway

The Nuclear Orphan Receptor NR2F6 Promotes Hepatic Steatosis through Upregulation of Fatty Acid Transporter CD36

Loss of CD36 Impairs Hepatic Insulin Signaling by Enhancing the Interaction of PTP1B with IR.

Long Noncoding RNA Licensing of Obesity-Linked Hepatic Lipogenesis and NAFLD Pathogenesis

Hepatic Lipid Accumulation Induced by a High‐fat Diet is Regulated by Nrf2 Through Multiple Pathways

Role of CD36 in the formation of non-alcoholic fatty liver disease in mice

A novel peptide encoded by circ-SLC9A6 promotes lipid dyshomeostasis through the regulation of H4K16ac-mediated CD36 transcription in NAFLD

1572-P: Lipotoxicity-Induced TET1 Mediates CD36 DNA Demethylation in Liver Macrophages to Aggravate NAFLD Progression

[KLF9 Regulates Hepatic Lipid Metabolism Via Inducing CD36 Expression].

Hepatic DKK1-driven steatosis is CD36 dependent

Hepatic CD147 Knockout Modulates Liver Steatosis and Up-Regulates Autophagy in High-Fat-diet-induced NAFLD Mice.